{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:02:51Z","timestamp":1770483771453,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.contraception.2011.08.014","type":"journal-article","created":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T20:46:12Z","timestamp":1318020372000},"page":"389-393","source":"Crossref","is-referenced-by-count":15,"title":["Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism"],"prefix":"10.1016","volume":"85","author":[{"given":"Cristina Aparecida Falbo","family":"Guazzelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Augusto","family":"Barreiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Regina","family":"Torloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.08.014_bb0005","first-page":"30","article-title":"Rationale for new oral contraceptive dosing","volume":"49","author":"Williams","year":"2004","journal-title":"Int J Fertil Womens Med"},{"key":"10.1016\/j.contraception.2011.08.014_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/humupd\/5.6.565","article-title":"The recent saga of cardiovascular disease and safety of oral contraceptives","volume":"5","author":"Edwards","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2011.08.014_bb0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/humrep\/16.3.469","article-title":"Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol","volume":"16","author":"Roumen","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.08.014_bb0020","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1067\/mob.2002.122988","article-title":"Acceptance of altering the standard 21-day\/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms","volume":"186","author":"Sulak","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.08.014_bb0025","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJM198109103051104","article-title":"Oral contraceptives and cardiovascular diseases. First of two parts","volume":"305","author":"Stadel","year":"1981","journal-title":"New Eng J Med"},{"key":"10.1016\/j.contraception.2011.08.014_bb0030","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJM198109173051205","article-title":"Oral contraceptives and cardiovascular diseases. Second of two parts","volume":"305","author":"Stadel","year":"1981","journal-title":"New Eng J Med"},{"key":"10.1016\/j.contraception.2011.08.014_bb0035","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/106002809502907-817","article-title":"Desogestrel, norgestimate, and gestodene: the newer progestins","volume":"29","author":"Kaplan","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.contraception.2011.08.014_bb0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3109\/00016349409013416","article-title":"Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone","volume":"73","author":"Akerlund","year":"1994","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2011.08.014_bb0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.contraception.2004.06.001","article-title":"Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg)","volume":"70","author":"Machado","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.08.014_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.contraception.2009.07.011","article-title":"Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use","volume":"81","author":"Wiegratz","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.08.014_bb0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.contraception.2004.01.004","article-title":"The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study","volume":"69","author":"Tuppurainen","year":"2004","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2011.08.014_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.contraception.2010.11.002","article-title":"Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism","volume":"84","author":"Barreiros","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.08.014_bb0065","series-title":"Medical eligibility criteria for contraceptive use. Reproductive Heath and Research","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.contraception.2011.08.014_bb0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.contraception.2011.08.014_bb0075","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJM199011153232003","article-title":"The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism","volume":"323","author":"Godsland","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.08.014_bb0080","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/0002-9378(88)90199-8","article-title":"Oral contraception and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins","volume":"158","author":"Crook","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.08.014_bb0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0010-7824(97)00010-3","article-title":"Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin","volume":"55","author":"Crook","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.08.014_bb0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.contraception.2004.08.017","article-title":"A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel","volume":"71","author":"Skouby","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.08.014_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0010-7824(01)00224-4","article-title":"Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size","volume":"64","author":"Foulon","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.08.014_bb0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2011.08.014_bb0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"issue":"372","key":"10.1016\/j.contraception.2011.08.014_bb0110","first-page":"185","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case\u2013control study","volume":"19","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.08.014_bb0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2796.2003.01276.x","article-title":"Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid modifying therapy","volume":"255","author":"Walldius","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.contraception.2011.08.014_bb0120","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jacc.2007.09.060","article-title":"High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies","volume":"51","author":"van der Steeg","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.contraception.2011.08.014_bb0125","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1210\/jc.2009-1402","article-title":"Increased apolipoprotein AI production rate and redistribution of high-density lipoprotein size induced by estrogen plus progestin as oral contraceptive","volume":"94","author":"Duvillard","year":"2009","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411004938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411004938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T18:48:35Z","timestamp":1593110915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411004938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0010782411004938"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.08.014","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}